Alan Nurden: How Platelet Integrins Intervene in Cancer Metastasis and Tumor Development
Alan Nurden, Emeritus Research Director at CNRS, Co-Founder of the French National Reference Centre for Inherited Platelet Disorders (CRPP), shared a post on LinkedIn about a recent article by Emily Janus-Bell et al, published in Cell Press:
“Up to now, studies on patients with Glanzmann thrombasthenia (GT) and platelets either lacking the alphaIIbbeta3 integrin or with mutations limiting its function have contributed to advances in the treatment of cardiovascular diseases and in particular, arterial thrombosis, where this integrin has a key role.
However, in a recent paper, Emily Janus-Bell and her colleagues used mouse models to underline how platelet integrins also intervene in cancer metastasis and tumor development. So, is the evolution of cancer in GT patients different? In fact, this same question applies to diabetes and all major inflammatory and viral-induced pathologies where platelets and their integrins may intervene in one way or another. International databases need to be set up to help answer these questions.
Not only for arterial and venous thrombosis, treatment of all major illnesses in GT patients may require special thought.”
Title: Depletion of all platelet integrins impacts hemostasis, thrombosis, and tumor metastasis
Authors: Emily Janus-Bell, Cristina Liboni, Alexandra Yakusheva, Vincent Mittelheisser, Clarisse Mouriaux, Catherine Bourdon, Louis Bochler, Vincent Hyenne, Maria Garcia-Leon, Olivier Lefebvre, Jacky G. Goetz, Pierre H. Mangin
Read the Full Article on Cell Press.
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 21, 2026, 08:29Andreas Kronbichler: The Changing Landscape of CV Risk in ANCA-Associated Vasculitis
-
Oct 21, 2026, 08:21Pham Quy: Taking Stroke Awareness Beyond Hospitals and Into the Community
-
Oct 21, 2026, 07:15Mahmoud Saad: Successful Mechanical Thrombectomy for Right Atrial Thrombosis
-
Oct 21, 2026, 06:55Hunain Shahbaz: Extended Dual Antiplatelet Therapy Beyond 12 Months After Drug-Eluting Stent Implantation
-
Oct 21, 2026, 06:19Dawood Findakly: When Should Anticoagulation Be Held or Resumed?
-
Oct 21, 2026, 03:36Steve Watson: Ligand Epitope Ratios Influence Antagonist Inhibition
-
Oct 21, 2026, 03:18Stephen D. Coombs: Superficial Venous Thrombosis in Athletes and Importance of Early Recognition and Referral
-
Oct 21, 2026, 02:52Aymar Akilimali: Bleeding During Anticoagulation as a Potential Signal of Occult Cancer
-
Oct 21, 2026, 00:58Anees Ur Rahman: Completing a Two-Week Clinical Rotation at Haemophilia Treatment Centre Rawalpindi